225 related articles for article (PubMed ID: 24116172)
1. The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study.
Sukowati CH; Anfuso B; Torre G; Francalanci P; Crocè LS; Tiribelli C
PLoS One; 2013; 8(10):e76830. PubMed ID: 24116172
[TBL] [Abstract][Full Text] [Related]
2. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.
Sun Z; Zhao Z; Li G; Dong S; Huang Z; Ye L; Liang H; Qu J; Ai X; Zhang W; Chen X
Tumori; 2010; 96(1):90-6. PubMed ID: 20437864
[TBL] [Abstract][Full Text] [Related]
3. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma.
Sukowati CH; Rosso N; Pascut D; Anfuso B; Torre G; Francalanci P; Crocè LS; Tiribelli C
BMC Gastroenterol; 2012 Nov; 12():160. PubMed ID: 23153066
[TBL] [Abstract][Full Text] [Related]
4. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
Jia Q; Zhang X; Deng T; Gao J
Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
[TBL] [Abstract][Full Text] [Related]
5. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
6. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
[TBL] [Abstract][Full Text] [Related]
7. Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver.
Chisaki I; Kobayashi M; Itagaki S; Hirano T; Iseki K
Biochim Biophys Acta; 2009 Nov; 1788(11):2396-403. PubMed ID: 19728987
[TBL] [Abstract][Full Text] [Related]
8. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance.
Li G; Chen X; Wang Q; Xu Z; Zhang W; Ye L
J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):173-5. PubMed ID: 17497289
[TBL] [Abstract][Full Text] [Related]
9. miR-589-5p inhibits MAP3K8 and suppresses CD90
Zhang X; Jiang P; Shuai L; Chen K; Li Z; Zhang Y; Jiang Y; Li X
J Exp Clin Cancer Res; 2016 Nov; 35(1):176. PubMed ID: 27835990
[TBL] [Abstract][Full Text] [Related]
10. Differential capacity of CD90+ cells in autophagy activation following chemotherapy in hepatocellular carcinoma.
Do HQ; Luong AB; Bonazza D; Bottin C; Doan TP; Tran LD; Truong NH; Tell G; Pham HL; Tiribelli C; Sukowati CH
Ann Hepatol; 2020; 19(6):645-652. PubMed ID: 32745631
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
12. Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells.
Pang E; Hu Y; Chan KY; Lai PB; Squire JA; Macgregor PF; Beheshti B; Albert M; Leung TW; Wong N
Lab Invest; 2005 May; 85(5):664-74. PubMed ID: 15765123
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma.
Park SY; Han J; Kim JB; Yang MG; Kim YJ; Lim HJ; An SY; Kim JH
Eur J Cancer; 2014 Jan; 50(2):341-50. PubMed ID: 24161763
[TBL] [Abstract][Full Text] [Related]
14. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of liver cancer stem cells by RNA-sequencing.
Ho DW; Yang ZF; Yi K; Lam CT; Ng MN; Yu WC; Lau J; Wan T; Wang X; Yan Z; Liu H; Zhang Y; Fan ST
PLoS One; 2012; 7(5):e37159. PubMed ID: 22606345
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma.
Namisaki T; Schaeffeler E; Fukui H; Yoshiji H; Nakajima Y; Fritz P; Schwab M; Nies AT
Drug Metab Dispos; 2014 Dec; 42(12):2033-40. PubMed ID: 25231932
[TBL] [Abstract][Full Text] [Related]
17. miR-125a/b inhibits tumor-associated macrophages mediated in cancer stem cells of hepatocellular carcinoma by targeting CD90.
Wang Y; Wang B; Xiao S; Li Y; Chen Q
J Cell Biochem; 2019 Mar; 120(3):3046-3055. PubMed ID: 30536969
[TBL] [Abstract][Full Text] [Related]
18. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.
Yamashita T; Honda M; Nakamoto Y; Baba M; Nio K; Hara Y; Zeng SS; Hayashi T; Kondo M; Takatori H; Yamashita T; Mizukoshi E; Ikeda H; Zen Y; Takamura H; Wang XW; Kaneko S
Hepatology; 2013 Apr; 57(4):1484-97. PubMed ID: 23174907
[TBL] [Abstract][Full Text] [Related]
19. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
[TBL] [Abstract][Full Text] [Related]
20. Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.
Takahata T; Ookawa K; Suto K; Tanaka M; Yano H; Nakashima O; Kojiro M; Tamura Y; Tateishi T; Sakata Y; Fukuda S
Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):399-407. PubMed ID: 18248513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
